European life sciences investor BioMedPartners has held its first closing of BioMedInvest II, the company’s second venture capital fund, at CHF95m (€64m).
BioMedInvest II is a healthcare-dedicated fund which invests in early to mid-stage companies in Switzerland, Germany and neighbouring countries of the European Union.
The fund is backed by both existing and new investors, including the lead investor ERP-EIF Dachfonds.
